Status:
UNKNOWN
Neoadjuvant Therapy of Icotinib in Epidermal Growth Factor Receptor Mutated NSCLC Patients
Lead Sponsor:
Betta Pharmaceuticals Co., Ltd.
Conditions:
Non-small-cell Lung Cancer
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate the overall response rate and disease free survival for IIIAN2 non-small-cell lung cancer patients with EGFR 19 or 21 exon mutation.
Detailed Description
Neoadjuvant therapy has been used for years to treat patients with non-small-cell lung cancer whose primary tumors are too large to allow for surgery. Reduction in size of the primary tumor with neoad...
Eligibility Criteria
Inclusion
- The patients signed the written informed consent. 2.The patients present with operable IIIAN2 non-small-cell lung cancers with 19 or 21 exon mutation.
- The patients have no history of anti-cancer therapies including chemotherapy, radiation therapy, and surgical therapy.
- The patients' Eastern Cooperative Oncology Group scores are ≤ 0-1. 5.The age of patient is ≥ 18 years old with a life expectancy longer than 3 months.
Exclusion
- 1\. Patients with unresected tumor. 2. Wild EGFR type. 3. Allergic to the study drug. 4. Patients have severe non-cancerous diseases. 5. Patients are undergoing current administration of anti-cancer therapies, or are attending some other clinical trials.
Key Trial Info
Start Date :
April 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2018
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT01843647
Start Date
April 1 2013
End Date
February 1 2018
Last Update
July 15 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhejiang cancer hospital
Hangzhou, Zhejiang, China, 310022